Compare ATEX & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEX | DRTS |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2014 | 2021 |
| Metric | ATEX | DRTS |
|---|---|---|
| Price | $84.06 | $14.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $112.33 | $17.80 |
| AVG Volume (30 Days) | 234.7K | ★ 441.6K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 891.80 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $6,501,000.00 | N/A |
| Revenue This Year | $220.44 | N/A |
| Revenue Next Year | N/A | $1,235.59 |
| P/E Ratio | $8,558.00 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $17.58 | $3.43 |
| 52 Week High | $113.00 | $15.79 |
| Indicator | ATEX | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 48.43 |
| Support Level | $81.61 | $13.73 |
| Resistance Level | $87.28 | $15.01 |
| Average True Range (ATR) | 3.93 | 0.58 |
| MACD | 0.79 | -0.09 |
| Stochastic Oscillator | 76.11 | 13.18 |
Anterix Inc is the holder of licensed 900 MHz spectrum (896-901/935-940 MHz) with coverage spanning the contiguous United States, Hawaii, Alaska, and Puerto Rico. The Company is focused on commercializing its spectrum assets and delivering intelligent infrastructure solutions, including private broadband networks, tower access, and turnkey connectivity management, to utility and critical infrastructure enterprises. It provides mission-critical private 900 MHz spectrum to the utility sector and integrated deployment solutions that support a secure, resilient, and decarbonized future. Its solutions include 900 MHz Private Wireless, TowerX, and CatalyX.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.